ArticleInflammopharmacology2026
Drimiopsis maculata methanol extract attenuates inflammation in experimental rat model of polyarthritis: a biochemical and molecular insight.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Drimiopsis maculata is a member of Asparagaceae family, has been used to treat inflammatory and pain conditions since long. The intention of performing this study was to determine anti-inflammatory properties in polyarthritis in D. maculata methanol extract (DMME). The extract was phytochemically characterized using proximate analysis, HPLC and GCMS profiling. DMME 200, 400, and 600 mg/kg were used to evaluate in vivo efficacy in formaldehyde-induced polyarthritis rat model. Diameter of paw, body weight, arthritic score, hematological indices, and biochemical markers were among the parameters that were assessed. Levels of HSP-70, PGE-2, NO, iNOS, IL-6, TNF-α, SOD, CAT, and MDA were quantified using ELISA. Inflammatory gene expression was determined by qRT-PCR. Organ Histological and radiological examinations were also carried out. Phytochemical evaluation confirmed the presence of various secondary metabolites, with HPLC and GCMS detecting diverse bioactive compounds. In vivo, treatment with DMME showed a dose-dependent decrease in paw inflammation and polyarthritis severity. Improvements were noted in hematological and biochemical characteristics, along with histological indication of decreased inflammation, bone degradation, and pannus formation. Analysis of gene expression revealed that anti-inflammatory genes were up-regulated whereas pro-inflammatory mediators were down-regulated. The outcomes of this research study show that DMME holds strong anti-inflammatory potential and provide scientific ground supporting its conventional use in the management of inflammation in polyarthritis.
Indexed as
Identifiers
41483284What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.